Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 13/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.36 |
| ▸ | CLK2 | P49760 | 5/20 | 0.36 |
| ▸ | CLK3 | P49761 | 5/20 | 0.36 |
| ▸ | WNT1 | P04628 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 10/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25938176 | 0.79 | CDK7 (0.45) | CDK7DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL25936054 | 0.75 | JAK2 (0.38) | — | |
| SCHEMBL24137846 | 0.74 | CDK7 (0.52) | CDK7DYRK1ACLK2CLK3CDK2 | |
| SCHEMBL25936076 | 0.69 | JAK2 (0.48) | CDK7DYRK1ACLK2CDK2CDK1 | |
| SCHEMBL25936083 | 0.68 | MAPK1 (0.46) | — | |
| SCHEMBL24137560 | 0.67 | CDK2 (0.57) | CDK7DYRK1AWNT1CDK2CDK1 | |
| SCHEMBL24137727 | 0.67 | JAK2 (0.52) | CDK7DYRK1ACLK2CDK2CDK1 | |
| SCHEMBL25936215 | 0.66 | JAK2 (0.50) | CDK7DYRK1ACLK2WNT1CDK2 | |
| SCHEMBL25936105 | 0.65 | MAPK1 (0.43) | — | |
| SCHEMBL22382964 | 0.64 | CDK7 (0.43) | CDK7DYRK1ACLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | CDK7 210/4885DYRK1A 495/4885CLK2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.